Ligand Pharmaceuticals Incorporated (LGND) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Clear recent catalyst and guidance upside: on 2026-04-27 Ligand acquired XOMA Royalty, expanding the royalty portfolio to more than 200 assets and seven commercial products, expected to be immediately accretive, while management raised 2026 adjusted EPS guidance to $8.50-$9.50.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Exceptional Margins ⢠Strong Liquidity ⢠Rich Valuation LGND delivered exceptional 2025 margins, strong liquidity, and low leverage, but recent quarterly earnings were volatile, cash conversion lagged profits, and the stock appears richly valued.
Price Behavior
Key Price Behavior Insights: ⢠Higher highs ⢠Key support ⢠Near-term resistance Support Level: $229-$230 Resistance Level: $236-$237 Over the last month, LGND climbed from $210.33 to $237.00 and remains bullish as long as it holds above $229-$230, with a break above $237 needed to confirm the next upside leg.
Sentiment & News
Key News Insights: ⢠Royalty Expansion ⢠Accretive Deal ⢠Investor Outreach Ligand is sharpening its royalty-aggregation strategy with a $739 million, immediately EPS-accretive acquisition of XOMA Royalty, while reinforcing investor engagement and growth in commercial royalties.
AI Summary
LGND should now be viewed less as a passive royalty collector and more as an active royalty-aggregation platform, with the accretive XOMA acquisition making disciplined deal sourcing and integration the main drivers of upsideâbut at a rich valuation, the stock only works if management consistently executes and avoids overpaying. #M&Aâ
Description
Ligand Pharmaceuticals develops or acquires technologies that support pharmaceutical companies in discovering and developing medicines, commercializing a portfolio that spans oncology, infectious disease, endocrine and bone health, vaccines, and other specialty treatments. The company also partners on and licenses programs in clinical development targeting cancer, neurological, metabolic, cardiovascular, and other conditions, and it manufactures Captisol excipient materials. Founded in 1987, Ligand is headquartered in Emeryville, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 28 | May 5 | LGND | Ligand Pharmaceuticals Incorporated | Clear recent catalyst and guidance upside: on 2026-04-27 Ligand acquired XOMA Royalty, expanding the royalty portfolio to more than 200 assets and seven commercial products, expected to be immediately accretive, while management raised 2026 adjusted EPS guidance to $8.50-$9.50. | Closed | -0.0% |